Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

Hmm, I think it will take longer to see an effect, though, since these are earlier stage patients than we've seen before. High-risk, earlier stage patients may take several years to reach a median in recurrence-free survival, so it may take time even if Axal is working in these patients.

I caution heavily against looking at enrollment timing as some sort of gauge for how patients are doing. Too many variables to be reliable.